Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omtriptolide - Pharmagenesis/Pierre Fabre

Drug Profile

Omtriptolide - Pharmagenesis/Pierre Fabre

Alternative Names: F 60008; PG 49088; PG490-88Na; TriptoSar

Latest Information Update: 13 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmagenesis
  • Developer Pharmagenesis; Pierre Fabre
  • Class Antineoplastics; Phenanthrenes; Small molecules
  • Mechanism of Action Apoptosis stimulants; Calcium channel modulators; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Myeloid leukaemia; Solid tumours
  • Discontinued Graft-versus-host disease

Most Recent Events

  • 13 Jun 2018 Phase I development in Solid tumours and Myeloid leukaemia is ongoing in USA and France respectively (Pharmagenesis pipeline, June 2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Injection)
  • 19 Oct 2015 Phase-I development is ongoing in Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top